Free Trial

Equillium (EQ) Competitors

Equillium logo
$0.42 -0.01 (-1.40%)
Closing price 04:00 PM Eastern
Extended Trading
$0.43 +0.01 (+3.35%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EQ vs. MDCX, NBRV, APLT, PLUR, PRLD, MURA, ATNM, SCLX, GRCE, and XCUR

Should you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Medicus Pharma (MDCX), Nabriva Therapeutics (NBRV), Applied Therapeutics (APLT), Pluri (PLUR), Prelude Therapeutics (PRLD), Mural Oncology (MURA), Actinium Pharmaceuticals (ATNM), Scilex (SCLX), Grace Therapeutics (GRCE), and Exicure (XCUR). These companies are all part of the "pharmaceutical products" industry.

Equillium vs. Its Competitors

Medicus Pharma (NASDAQ:MDCX) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

In the previous week, Medicus Pharma had 2 more articles in the media than Equillium. MarketBeat recorded 3 mentions for Medicus Pharma and 1 mentions for Equillium. Medicus Pharma's average media sentiment score of 1.09 beat Equillium's score of 0.40 indicating that Medicus Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medicus Pharma
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Equillium
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Medicus Pharma has a net margin of 0.00% compared to Equillium's net margin of -19.62%. Equillium's return on equity of -74.34% beat Medicus Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Medicus PharmaN/A -380.03% -224.22%
Equillium -19.62%-74.34%-46.75%

Medicus Pharma presently has a consensus price target of $23.50, indicating a potential upside of 655.63%. Equillium has a consensus price target of $3.00, indicating a potential upside of 622.72%. Given Medicus Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Medicus Pharma is more favorable than Equillium.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medicus Pharma
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.50
Equillium
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

27.1% of Equillium shares are owned by institutional investors. 11.2% of Medicus Pharma shares are owned by company insiders. Comparatively, 31.6% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Equillium has higher revenue and earnings than Medicus Pharma. Medicus Pharma is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicus PharmaN/AN/A-$11.16M-$1.16-2.68
Equillium$41.10M0.36-$8.07M-$0.39-1.06

Summary

Equillium beats Medicus Pharma on 8 of the 15 factors compared between the two stocks.

Get Equillium News Delivered to You Automatically

Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EQ vs. The Competition

MetricEquilliumMED IndustryMedical SectorNASDAQ Exchange
Market Cap$15.04M$2.96B$5.54B$9.41B
Dividend YieldN/A2.46%3.75%4.03%
P/E Ratio-1.068.2821.0120.09
Price / Sales0.36303.17433.8199.01
Price / CashN/A42.5936.1658.27
Price / Book0.777.678.125.65
Net Income-$8.07M-$55.28M$3.25B$257.91M
7 Day Performance18.60%2.50%0.97%2.09%
1 Month Performance28.71%11.70%7.36%11.13%
1 Year Performance-54.38%4.89%31.31%18.40%

Equillium Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EQ
Equillium
2.5681 of 5 stars
$0.42
-1.4%
$3.00
+622.7%
-54.6%$15.04M$41.10M-1.0640
MDCX
Medicus Pharma
2.5064 of 5 stars
$3.40
+0.6%
$23.50
+591.2%
N/A$45.88MN/A-2.93N/AGap Up
High Trading Volume
NBRV
Nabriva Therapeutics
N/AN/AN/AN/A$45.46M$35.59M0.0070
APLT
Applied Therapeutics
4.5429 of 5 stars
$0.34
+4.9%
$6.10
+1,717.6%
-91.7%$45.30M$460K-0.7830Positive News
PLUR
Pluri
3.5764 of 5 stars
$5.79
+0.2%
$12.00
+107.3%
-5.6%$45.28M$330K-1.05150Positive News
Gap Down
PRLD
Prelude Therapeutics
3.7171 of 5 stars
$0.81
+1.6%
$4.50
+457.8%
-86.8%$44.82M$7M-0.48120
MURA
Mural Oncology
3.4567 of 5 stars
$2.48
-3.9%
$12.00
+383.9%
-28.4%$44.55MN/A-0.32119
ATNM
Actinium Pharmaceuticals
2.1347 of 5 stars
$1.42
-1.4%
$4.00
+181.7%
N/A$44.30MN/A-1.0230Positive News
SCLX
Scilex
2.5935 of 5 stars
$6.25
-1.7%
$455.00
+7,180.0%
-86.4%$44.21M$50.71M-0.2280Positive News
Gap Up
GRCE
Grace Therapeutics
2.6051 of 5 stars
$3.00
-4.2%
$12.00
+300.0%
N/A$43.28MN/A-3.37N/APositive News
XCUR
Exicure
1.518 of 5 stars
$6.47
-4.6%
N/A+2,395.1%$42.83M$500K-1.6950Positive News
Gap Up

Related Companies and Tools


This page (NASDAQ:EQ) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners